Future Continuous Manufacturing and Advanced Crystallisation Research Hub

我们的中心研究是由社会需要通过新的制造工艺生产现代生活的药物和材料。制造这些高价值产品的行业的巨大价值估计每年产生500亿英镑。在英国经济中。为了确保这个巨大的英国产业的国际竞争力，我们必须紧急创造新的方法来快速设计这些系统，控制分子如何自组装成小晶体，以便最好地为患者和客户配制和提供这些。我们还必须开发工程工具、工艺操作和控制方法，以资源高效的方式制造这些产品，同时提供最高质量的材料。改变这些材料的制造方式，从所谓的“批量”结晶（使用大容量罐）到“连续”结晶（更动态的“流动”过程）具有许多优点，包括更小的设施、更有效地使用昂贵的成分如溶剂、减少能量需求、资本投资、营运资本、最小化风险和变化，并且至关重要的是，改善对颗粒质量和性能的控制，使它们更适合于配制成最终产品。我们的愿景是快速可靠地设计一种工艺，使用高效的连续工艺将给定的材料制造成理想的颗粒，并确保将其有效地交付给消费者。这将使精准药物和其他高度定制的项目更快地推向市场。一个范例是与英国癌症研究中心的令人兴奋的创新伙伴关系。我们的研究将开发强大的设计程序，以快速开发新的颗粒产品和创新工艺，整合结晶和配方，以消除加工步骤，并开发灵活生产的重新配置策略。这将加速创新，实现重新分配的制造、更个性化的产品以及更贴近患者/客户的制造。我们将开发一个用于集成粒子工程的模块化MicroFactory，再加上完全集成的计算机建模方法，以指导分子，粒子和配方水平的工艺和材料设计。这将有助于优化我们所谓的以患者为中心的供应链，并提供可定制的产品。我们将更多地利用针对性的实验设计、预测和先进的计算机模拟新配方材料，以控制和优化生产过程。我们才华横溢的科学家团队将使用获奖的3400万英镑CMAC国家设施在斯特拉斯克莱德和我们的6个领先的大学辐条（巴斯，剑桥，帝国，利兹，拉夫堡，谢菲尔德）的杰出能力。这是建立在现有基础上的，被全球业界独立认可为“工业界，学术界和政府之间的典范合作，代表了制药制造和供应链研发框架的未来”。我们的愿景将通过合作伙伴关系和3100万英镑的共同投资从研究转化为产业。其中包括世界上最大的10家制药公司（如阿斯利康，葛兰素史克），化学品和食品公司（先正达、禾大、玛氏）和19家关键技术公司（西门子，15家中小企业）与Catapult（CPI）等创新辐条一起，我们的目标是为英国提供最先进的综合能力，以实现连续制造，从而获得更好的材料，更好的价值，更可持续和灵活的流程，为英国和全世界人民提供更好的健康和福祉。CMAC将为英国在药品制造和化学品领域创造未来的竞争优势，并得到行业/政府机构的大力支持，将英国定位为未来研究和制造投资的投资地点选择。

Our Hub research is driven by the societal need to produce medicines and materials for modern living through novel manufacturing processes. The enormous value of the industries manufacturing these high value products is estimated to generate £50 billion p.a. in the UK economy. To ensure international competitiveness for this huge UK industry we must urgently create new approaches for the rapid design of these systems, controlling how molecules self-assemble into small crystals, in order to best formulate and deliver these for patient and customer. We must also develop the engineering tools, process operations and control methods to manufacture these products in a resource-efficient way, while delivering the highest quality materials. Changing the way in which these materials are made, from what is called "batch" crystallisation (using large volume tanks) to "continuous" crystallisation (a more dynamic, "flowing" process), gives many advantages, including smaller facilities, more efficient use of expensive ingredients such as solvents, reducing energy requirements, capital investment, working capital, minimising risk and variation and, crucially, improving control over the quality and performance of the particles making them more suitable for formulation into final products. The vision is to quickly and reliably design a process to manufacture a given material into the ideal particle using an efficient continuous process, and ensure its effective delivery to the consumer. This will bring precision medicines and other highly customisable projects to market more quickly. An exemplar is the hubs exciting innovation partnership with Cancer Research UK. Our research will develop robust design procedures for rapid development of new particulate products and innovative processes, integrate crystallisation and formulation to eliminate processing steps and develop reconfiguration strategies for flexible production. This will accelerate innovation towards redistributed manufacturing, more personalisation of products, and manufacturing closer to the patient/customer. We will develop a modular MicroFactory for integrated particle engineering, coupled with a fully integrated, computer-modelling approach to guide the design of processes and materials at molecule, particle and formulation levels. This will help optimise what we call the patient-centric supply chain and provide customisable products. We will make greater use of targeted experimental design, prediction and advanced computer simulation of new formulated materials, to control and optimise the processes to manufacture them. Our talented team of scientists will use the outstanding capabilities in the award winning £34m CMAC National Facility at Strathclyde and across our 6 leading university spokes (Bath, Cambridge, Imperial, Leeds, Loughborough, Sheffield). This builds on existing foundations independently recognised by global industry as 'exemplary collaboration between industry, academia and government which represents the future of pharmaceutical manufacturing and supply chain R&D framework'. Our vision will be translated from research into industry through partnership and co-investment of £31m. This includes 10 of world's largest pharmaceutical companies (eg AstraZeneca, GSK), chemicals and food companies (Syngenta, Croda, Mars) and 19 key technology companies (Siemens, 15 SMEs) Together, with innovation spokes eg Catapult (CPI) we aim to provide the UK with the most advanced, integrated capabilities to deliver continuous manufacture, leading to better materials, better value, more sustainable and flexible processes and better health and well-being for the people of the UK and worldwide. CMAC will create future competitive advantage for the UK in medicines manufacturing and chemicals sector and is strongly supported by industry / government bodies, positioning the UK as the investment location choice for future investments in research and manufacturing.